HSP90AA1 and breast carcinoma: CRISPR–Cas9 deletion of Hsp90α in cell lines—including MDA-MB-231 breast cancer cells, mouse embryonic fibroblasts (MEFs), and others—had no effect on cell survival or proliferation [24,27].